Short Interest in Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Rises By 250.0%

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 2,800 shares, a growth of 250.0% from the February 28th total of 800 shares. Currently, 0.0% of the company's shares are sold short. Based on an average daily trading volume, of 531,600 shares, the short-interest ratio is currently 0.0 days.

Daiichi Sankyo Trading Down 2.1 %

Shares of DSNKY traded down $0.54 during trading hours on Monday, reaching $24.49. The stock had a trading volume of 234,256 shares, compared to its average volume of 245,356. The firm has a 50-day moving average of $24.92 and a 200 day moving average of $28.83. The company has a quick ratio of 2.11, a current ratio of 2.77 and a debt-to-equity ratio of 0.06. The company has a market cap of $46.73 billion and a P/E ratio of 28.47. Daiichi Sankyo has a 52 week low of $22.47 and a 52 week high of $42.48.

Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $0.22 EPS for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. On average, sell-side analysts expect that Daiichi Sankyo will post 0.73 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.